AI Article Synopsis
- - A national immunization program is crucial for preventing diseases and reducing mortality from vaccine-preventable diseases (VPD).
- - An analysis from 2001 to 2016 showed 13 confirmed cases of vaccine-related anaphylaxis in Korea, mainly in children, with the highest incidence in 2015.
- - Although vaccine-related anaphylaxis is rare, healthcare professionals need to remain vigilant about the possibility of such reactions.
Article Abstract
Background: A national immunization program (NIP) to prevent disease and reduce mortality from vaccine preventable diseases (VPD) is very important.
Methods: We analyzed only the anaphylaxis cases that occurred between 2001 and 2016 that Korea Centers for Disease Control and Prevention (KCDC) determined had a definite causal relationship with a vaccine. The clinical symptoms were assessed according to the Brighton Collaboration case definition (BCCD) level.
Results: During the period, there were 13 cases of vaccine-related anaphylaxis. The median age was 9 years (range, 1 month to 59 years). The incidence of anaphylaxis per million doses was 0.090 in 2005, 0.079 in 2012, 0.071 in 2013, 0.188 in 2015, and 0.036 in 2016. Of those cases, 23.1% were influenza vaccines, and 76.9% were BCCD level 2. Epinephrine was used in 46.2%.
Conclusion: Vaccine-related anaphylaxis seems to have been very rare in the past, but health care professionals must always be aware of anaphylaxis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521962 | PMC |
| http://dx.doi.org/10.3346/jkms.2020.35.e337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of leukocyte activation in suspected Non-IgE excipient-related COVID-19 vaccine reactions: An exploratory hypothesis-driven study of pathogenesis.
Allergy Asthma Proc
November 2024
Department of Pediatrics, Georgetown University School of Medicine, Washington, D.C.
Adverse allergic reactions due to the administration of vaccines developed for the protection of coronavirus disease 2019 (COVID-19) have been reported since the initiation of the vaccination campaigns in December 15, 2020. Current analyses provided by the Centers for Disease Control and Prevention and the U.S.
View Article and Find Full Text PDFNonclinical safety and immunogenicity assessment of a combined DTacP vaccine in animal models.
J Appl Toxicol
November 2024
Beijing Institute of Biological Products Company Limited, Beijing, China.
The (diphtheria, tetanus, and pertussis [acellular, component] [DTacP]) vaccine is a combined vaccine designed to prevent three potentially fatal diseases including pertussis, tetanus, and diphtheria in both children and adults. We utilized advanced technology to develop a novel DTacP vaccine that was previously unavailable in China. The nonclinical studies were performed to evaluate the immunogenicity, potential toxicity, and local tolerance of the vaccine in animal models.
View Article and Find Full Text PDFSurveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
Commun Dis Intell (2018)
June 2024
National Centre for Immunisation Research and Surveillance, The University of Sydney and The Children's Hospital at Westmead, Sydney, Australia.
This report summarises Australia's spontaneous (passive) surveillance data for adverse events following immunisation (AEFI) for coronavirus disease 2019 (COVID-19) vaccines in 2021 reported to the Therapeutic Goods Administration (TGA). The TGA strongly promoted and facilitated adverse event reporting in preparation for, and during, the COVID-19 vaccine rollout as a core component of the most intensive vaccine safety monitoring ever conducted in Australia. There were 111,348 AEFI reports for COVID-19 vaccines administered in 2021, an annual AEFI reporting rate of 271.
View Article and Find Full Text PDFDistinct Adverse Reactions to mRNA, Inactivated Virus, and Adenovirus Vector COVID-19 Vaccines: Insights from a Cohort Study on Atopic and Non-Atopic Subjects in Brazil.
Vaccines (Basel)
April 2024
Laboratory of Allergy and Clinical Immunology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-317, Brazil.
The emergence of COVID-19 caused by SARS-CoV-2 prompted an unprecedented global response to develop vaccines at an accelerated pace. Messenger RNA (mRNA) and adenovirus vector vaccines emerged as the frontrunners in global immunization efforts, significantly reducing hospitalization, severity, and mortality, supplemented by inactivated virus-based vaccines in developing countries. However, concerns regarding adverse effects, including allergic reactions, have been raised.
View Article and Find Full Text PDFSingle cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination.
Hum Vaccin Immunother
August 2023
Laboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.
Article Synopsis
- Phase I and II clinical trials indicate that inactivated SARS-CoV-2 vaccines have a good safety and immunogenicity profile, but two cases of adverse events, including fever and anaphylactic shock, were reported post-vaccination.
- Analysis through single-cell mRNA sequencing revealed that the patient with fever had increased cytotoxic CD8 T cells, possibly influenced by a concurrent Epstein-Barr virus infection, which boosted immune responses.
- The patient who experienced allergic shock had elevated S100A9 monocytes and activated CD4 T cells, indicating a complex cellular response linked to adverse reactions, illustrating the varied responses individuals may have to vaccination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!